Targeting Fibroblast Growth Factor Pathways in Prostate Cancer

被引：98

作者：

Corn, Paul G. ^{[1
]}

Wang, Fen ^{[2
]}

McKeehan, Wallace L. ^{[2
]}

Navone, Nora ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA

来源：

CLINICAL CANCER RESEARCH | 2013年 / 19卷 / 21期

关键词：

RECEPTOR TYROSINE KINASE; EPITHELIAL-CELL ANDROMEDIN; RAS/MAPK SIGNALING PATHWAY; ANDROGEN RECEPTOR; OVER-EXPRESSION; INTRAEPITHELIAL NEOPLASIA; MESENCHYMAL TRANSITION; CONDITIONAL ACTIVATION; MONOCLONAL-ANTIBODY; TISSUE HOMEOSTASIS;

D O I：

10.1158/1078-0432.CCR-13-1550

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Advanced prostate cancer carries a poor prognosis and novel therapies are needed. Research has focused on identifying mechanisms that promote angiogenesis and cellular proliferation during prostate cancer progression from the primary tumor to bone-the principal site of prostate cancer metastases. One candidate pathway is the fibroblast growth factor (FGF) axis. Aberrant expression of FGF ligands and FGF receptors leads to constitutive activation of multiple downstream pathways involved in prostate cancer progression including mitogen-activated protein kinase, phosphoinositide 3-kinase, and phospholipase C gamma. The involvement of FGF pathways in multiple mechanisms relevant to prostate tumorigenesis provides a rationale for the therapeutic blockade of this pathway, and two small-molecule tyrosine kinase inhibitors-dovitinib and nintedanib-are currently in phase II clinical development for advanced prostate cancer. Preliminary results from these trials suggest that FGF pathway inhibition represents a promising new strategy to treat castrate-resistant disease.

引用

页码：5856 / 5866

页数：11

共 84 条

[1]

Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition [J].

Acevedo, Victor D. ;

Gangula, Rama D. ;

Freeman, Kevin W. ;

Li, Rile ;

Zhang, Youngyou ;

Wang, Fen ;

Ayala, Gustavo E. ;

Peterson, Leif E. ;

Ittmann, Michael ;

Spencer, David M. .

CANCER CELL, 2007, 12 (06) :559-571

[2]

Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer [J].

Agarwal, Neeraj ;

Sonpavde, Guru ;

Sternberg, Cora N. .

EUROPEAN UROLOGY, 2012, 61 (05) :950-960

[3]

Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO

[4]

2-H

[5]

[Anonymous], CANC FACTS FIG 2012

[6]

GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling [J].

Bai, Ailin ;

Meetze, Kristan ;

Vo, Nhi Y. ;

Kollipara, Sriram ;

Mazsa, Elizabeth K. ;

Winston, William M. ;

Weiler, Solly ;

Poling, Laura L. ;

Chen, Ting ;

Ismail, Nesreen S. ;

Jiang, Jinwei ;

Lerner, Lorena ;

Gyuris, Jeno ;

Weng, Zhigang .

CANCER RESEARCH, 2010, 70 (19) :7630-7639

[7]

The FGF family: biology, pathophysiology and therapy [J].

Beenken, Andrew ;

Mohammadi, Moosa .

NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (03) :235-253

[8]

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients [J].

Bousquet, G. ;

Alexandre, J. ;

Le Tourneau, C. ;

Goldwasser, F. ;

Faivre, S. ;

de Mont-Serrat, H. ;

Kaiser, R. ;

Misset, J. L. ;

Raymond, E. .

BRITISH JOURNAL OF CANCER, 2011, 105 (11) :1640-1645

[9]

Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients [J].

Bubendorf, L ;

Schöpfer, A ;

Wagner, U ;

Sauter, G ;

Moch, H ;

Willi, N ;

Gasser, TC ;

Mihatsch, MJ .

HUMAN PATHOLOGY, 2000, 31 (05) :578-583

[10]

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors [J].

Casanovas, O ;

Hicklin, DJ ;

Bergers, G ;

Hanahan, D .

CANCER CELL, 2005, 8 (04) :299-309

← 1 2 3 4 5 6 7 8 9 →